ImmuneBridge is developing allogeneic immunotherapies for cancer.
ImmuneBridge has raised $7.7M in total funding. The most recent round was Seed. The last funding was announced in March 2026.
ImmuneBridge's investors include Insight Partners, Gaingels, Quiet Capital, NFX, Pioneer Fund.
ImmuneBridge is headquartered in San Francisco, United States.
ImmuneBridge is developing allogeneic immunotherapies for cancer.
ImmuneBridge is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ImmuneBridge — Funding & Investors." VCBacked, March 23, 2026, https://www.vcbacked.co/company/immunebridge. Accessed July 19, 2026.
VCBacked. (2026). ImmuneBridge — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/immunebridge
{{cite web |title=ImmuneBridge — Funding & Investors |url=https://www.vcbacked.co/company/immunebridge |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated